NICE no for Celgene's Vidaza violates Human Rights Act, say patient groups
This article was originally published in Scrip
Executive Summary
UK patient groups have lodged an appeal against health technology appraisal body NICE's decision to decline Celgene's anticancer, Vidaza (5-azacitidine), for patients with myelodysplastic syndromes (MDS). The patient groups say the recommendations are "incompatible" with the UK's 1998 Human Rights Act.